Insulin - A voice for choice

Insulin - A Voice for Choice

Volumn , Issue , 2007, Pages

  Teuscher, Arthur ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72949107525     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (126)

1. Jenkins JJ: Proprietary Names and the Drug Approval Process. Washington, Center for Drug Evaluation and Research, Office of New Drugs, 2003.
2. Teuscher A, Berger WG: Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987;ii:382-385.
3. Teuscher A, Egger M: Human insulin hypoglycaemia unawareness. Lancet 1989;i:1072.
4. World Health Organization: WHO Model Formulary 2002, p 319.
5. Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H, Yonekawa Y, Yamada Y, Fukuda K, Tsukiyama K, Suzuki H, Kawasaki Y, Shimodaira M, Matsuoka K, Shibata T, Kasai Y, Maekawa T, Shapiro J, Tanaka K: Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 2005;365:1642-1644.
6. Richter B, Neises G: 'Human' insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev 2005;1:CD003816. DOI: 10.1002/14651858.CD003816.pub2.
7. Cahill GF Jr, Etzwiler LD, Freinkel N: 'Control' and diabetes. N Engl J Med 1976;294:1004-1005.
8. DCCT, quoted in http://www.fmcsa.dot.gov/Pdfs/insulin4.pdf, p. 4-12 6.3.2007.
9. Pickup J, Mattock M, Kerry S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705.
10. Pickup J: How good is glycaemic control during CSII? Do we still need an artifi cial pancreas? Infusystems Int 2006;5:4.
11. Bliss M: The Discovery of Insulin. Chicago, University of Chicago Press, 1982, p 155.
12. Jersild M: Insulin zinc suspension; four years' experience. Lancet 1956;271:1009-1013.
13. Spencer AG, Morgans ME: Lente insulin; four years' experience. Lancet 1956;271:1013-1017.
14. Teuscher A: Treatment of insulin lipoatrophy with monocomponent insulin. Diabetologia 1974;10:211-214.
15. Ho LT, Lam HC, Wu MS, Kwok CF, Jap TS, Tang KT, Wang LM, Liu YF: A twelve month doubleblind randomized study of the efficacy and immunogenicity of human and porcine insulins in non-insulin-dependent diabetics. Zhonghua Yi Xue Za Zhi (Taipei) 1991;47:313-319.
16. Balsells M, Corcoy R, Mauricio D, Morales J, Garcia-Patterson A, Carreras G, Puig-Domingo M, de Leiva A: Insulin antibody response to a short course of human insulin therapy in women with gestational diabetes. Diabetes Care 1997;20:1172-1175.
17. Meienhofer J, Schnabel E, Bremer H, et al: Synthese der Insulinketten und ihre Kombination zu insulactiven Präparaten. Z Naturforsch 1963;18:1120.
18. Kung YT, Da YC, Huang WT, et al: Total synthesis of crystalline insulin. Sci Sin 1966;15:544.
19. Katsoyannis PG, Tometsko A, Zalut C: Insulin peptides XII. Human insulin generation by combination of synthetic A and B chains. J Am Chem Soc 1966;88:186.
20. Teuscher A: The biological effect of purely synthetic human insulin in patients with diabetes mellitus. Schweiz Med Wochenschr 1979;109:743-747.
21. Keen H, Glynne A, Pickup JC, et al: Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men. Lancet 1980;ii:398-401.
22. Berger W, Teuscher A: Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987;ii:382-385.
23. Deary IJ, Hepburn DA, MacLeod KM, et al: Partitioning the symptoms of hypoglycaemia using multi-sample confi rmatory factor analysis. Diabetologia 1993;36:771-777.
24. Glaser B, Leibowitz G: Hypoglycemia; in Joslin's Diabetes Mellitus, ed 14. Philadelphia, Lippincott Williams & Wilkins, 2005, pp 1150-1151.
25. Clausen Sjöborn N, Lins PE, Adamson U, Theodorsson E: A comparative study on the hormonal responses to insulin-induced hypoglycaemia using semi-synthetic human insulin and pork insulin in patients with type 1 diabetes mellitus. Diabetic Med 1990;7:775-779.
26. Fisher BM, Gray C, Beastall G, Frier BM: Responses to acute insulin-induced hypoglycaemia in diabetic patients. A comparison of short acting human and porcine insulins. Diab Res 1988;8:1-8.
27. Joslin EP: Diabetic Manual for the Doctor and Patient, ed 9. Philadelphia, Lea & Febiger, 1957, p 48.
28. Robbins DC, Normand EF, Colnes JP: Glucose response of diabetic patients to different carbohydrates. N Engl J Med 1984;310:1388-1389.
29. Sussmann KE: Failure of warning in insulin-induced hypoglycemic reactions. Diabetes 1963;12:38.
30. Letters patent of the AGPD (Arbeitsgemeinschaft für Pädiatrische Diabetologie) to Novo Nordisk, January 21, 2006.
31. Strasser D, Nutzi E, Spinas GA, Berger W: Treatment of early-morning hyperglycemia in type 1 diabetics with amorphous zinc insulin (Semilente) at bedtime. Horm Res 1993;39:173-178.
32. Chico A, Vidal-Rios P, Subira M, Novials A: The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26:1153-1157.
33. Amiel SA, Tamborlane WB, Simonson DC, Sherwin RS: Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 1987;316:1376-1383.
34. Masharani U, Karam JH: Diabetes Mellitus and Hypoglycemia; in Current Medical Diagnosis and Treatment. New York, Lange Medical Books, 2001, p 1188.
35. Amiel S: Joslin's Diabetes Mellitus, ed 14. Philadelphia, Lippincott, 2005, p 675.
36. Physician's Desk Reference (PDR), ed 59. Montvale, Thompson, 2005, p 1855.
37. Teuscher A, Berger W: Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987;ii:382-385.
38. Teuscher A, Berger W: Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987;ii:382-385.
39. Cox DJ, Gonder-Frederick LA, Kovatchev BP, Julian DM, Clarke WL: Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care 2000;23:163-170.
40. FMCSA Medical Reports: Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, FMCSA-MCP-02-002, October 2002, part IV, pp 70-92. http://www.fmcsa.dot.gov/Pdfs/insulin4.pdf.
41. Cox DJ, Penberthy JK, Zrebiec J, et al: Diabetes and Driving Mishaps. Frequency and correlations from a multinational survey. Diabetes Care 2003;26:2329-2334.
42. Schweizerische Diabetesgesellschaft: Diabetes & Autofahren: Gute Werte? - Gute Fahrt! 2005
43. IDDT Newsletter, January 2005, p 9
44. Deutscher Diabetiker Bund Landesverband Hamburg e.V. Führerschein und Autofahren. http:// www.diabetikerbund-hamburg.de/informationen/autofahr.htm 4.2.2005.
45. Haertel F: Tödlicher Blackout. Focus 1994, vol 46, p 44.
46. Weston PJ, Gill GV: Is undetected autonomic dysfunction responsible for sudden death in type 1 diabetes mellitus? The 'dead in bed' syndrome revisited. Diabet Med 1999;16:626-631.
47. Joslin EP: Joslin's Diabetes Mellitus, ed 12. Philadelphia, Lea & Febiger, 1985, p 402.
48. Teuscher, A: Tot-im-Bett-Syndrom. Subkutan July 1996;15:16-17.
49. B.J., B.E.: Letter to the Editor. Subkutan October 1996;15:30.
50. Teuscher A, Berger WG: Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987;ii:382-385.
51. Tattersall RB. Drug Ther Bull 1989.
52. Redmond S: Changing to human insulin. Balance 1988;106:66-68.
53. Toseland PA: Editorial. Med Sci Law 1990;30:2.
54. Tattersall R: Diabetes deaths and human insulins. The Guardian, Aug 10, 1989.
55. The human factor: artificial insulin is now available as an alternative to insulin from animals. The Economist, Oct 21, 1989.
56. Tattersall RB, Gill GV: Unexplained deaths of type 1 diabetic patients. Diabet Med 1991;8:49-58.
57. Thordarson H, Søvik O: Dead-in-bed syndrome in young diabetic patients. Diabet Med 1995;12:782-787.
58. Sovik O, Thordarson H: Dead-in-bed syndrome in young diabetic patients. Diabetes Care 1999;22(suppl 2):B40-42.
59. Borch-Johnsen K, Helweg-Larsen K: Sudden death and human insulin: is there a link? Diabet Med 1993;10:255-259
60. Wibell L, Nyström L, Östman J, Anrqvist H, Blohmé G, Lithner F, Littorin B, Sundkvist G: Increased mortality in diabetes during the first 10 years of the disease. A population-based study (DISS) in Swedish adults 15-34 years old at diagnosis. J Intern Med 2001;249:263.
61. BBC News, Dec 16, 1999
62. Jacobson AM, et al: Diabetes, the brain, and behavior: is there a biological mechanism underlying the association between diabetes and depression? Int Rev Neurobiol 2002;51:455-479
63. Wandell PE: Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries. Scand J Prim Health Care 2005;23:68-74.
64. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:982.
65. Rankins D, Wellard RM, Cameron F, et al: The impact of acute hypoglycemia on neuropsychological and neurometabolite profiles in children with type 1 diabetes. Diabetes Care 2005;28:2771-2773.
66. Smid HGOM, Trümper BG, Pottaq G, et al: Differentiation of hypoglycaemia induced cognitive impairments: an electrophysiological approach. Brain 1997;120:1041-1056.
67. MacLeod KM, Hepburn DA, Deary IJ, et al: Regional cerebral blood fl ow in IDDM patients: effects of diabetes and of recurrent severe hypoglycaemia. Diabetologia 1994;37:257-263.
68. McIntyre RS, Konarski JZ, Misener VL, et al: Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005;17:83-93.
69. Noh JH, Park JK, Lee HJ, et al: Depressive symptoms of type 2 diabetics treated with insulin compared to diabetics taking oral anti-diabetic drugs: a Korean study. Diabetes Res Clin Pract 2005;69:243-248.
70. Richter B, Neises G: 'Human' insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev 2005;1:CD003816. DOI: 10.1002/14651858.CD003816.pub2.
71. US Food and Drug Administration: NDA 18,780 and 18,781, Medical Officers' Review (MOR) of New Drug Application (NDA), July 20, 1982
72. Clark AJ, Adeniyi-Jones RO, Knight G, Leiper JM, Wiles PG, Jones RH, Keen H, MacCuish AC, Ward JD, Watkins PJ, Cauldwell JM, Glynne A, Scotton JB: Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients. Lancet 1982;ii:354-357.
73. Møller-Jensen B, Kühl C: Investigation of the safety and efficacy of Actrapid HM and Protaphane HM. Data on file Hvidore Hospital, Klampenborg, 1982/1983.
74. L'Etang H-JC: Diabetes Mellitus. Achievements and Scepticism. Int Congr Symp Ser No 77. London, Royal Society of Medicine, 1984, p 141.
75. Berger WG, Althaus BU: Reduced awareness of hypoglycemia after changing from porcine to human insulin in IDDM. Diabetes Care 1987;10:260.
76. Teuscher A, Berger WG: Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987;ii:382-385.
77. Kappeler D (President of the Medical Committee of the Swiss Diabetes Association): Television transmission SF DRS, September 24, 1987. (Translation taken from Dejgaard A: Awareness of hypoglycaemia during treatment with human insulin, confidential report, Novo, October 16, 1987.)
78. Teuscher A, Egger M: Human insulin hypoglycaemia unawareness. Lancet 1989;1:1072.
79. Berger W, Keller U, Honegger B, Jaeggi E: Warning symptoms of hypoglycaemia during treatment with human and porcine insulin in diabetes mellitus. Lancet 1989;i:1041-1044.
80. Egger M, Smith GD, Teuscher AU, Teuscher A: Infl uence of 'human' insulin on symptoms and awareness of hypoglycemia: a randomized double blind crossover trial. BMJ 1991;303:622-626.
81. Rosak C, AlthoffPH, Enzmann F, Schoffl ing K: Comparative studies on intermediary metabolism and hormonal counterregulation following human insulin (recombinant DNA) and purified pork insulin in man. Diabetes Care 1982;5(suppl 2):82-89.
82. Schluter KJ, Enzmann F, Kerp L: Different potencies of biosynthetic human and purified porcine insulin. Horm Metab Res 1983;15:271-274.
83. BNF (British National Formulary), No 25. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London, March 1993, p 255.
84. Owens DR, Vora JP, Heding LG, Luzio S, Ryder RE, Atiea J, Hayes TM: Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man. Diabet Med 1986;3:326-329.
85. Egger M, Smith GD, Imhoof H, Teuscher A: Risk of severe hypoglycaemia in insulin treated diabetic patients transferred to human insulin: a case control study. BMJ 1991;303:617-621.
86. Iles S: Thesis/Project University of Southampton, General Hospital Wessex, Medical Library book No. 93131296, 1992.
87. Smith R: Letter. Novo Nordisk Bull, Jan 1992, p 21.
88. Colagiuri S, Miller JJ, Petocz P: Double-blind crossover comparison of 'human' and porcine insulins in patients reporting lack of hypoglycemia awareness. Lancet 1992;339:1432-1435.
89. Egger M, Smith GD: Letter to the editor. Lancet 1992;340:301.
90. Teuscher A: Letter to the editor. Lancet 1992;340:301-302.
91. von Kriegstein E: Letter to the editor. Lancet 1992;340:302.
92. Maran A, Lomas J, Archibald H, et al: Double-blind clinical and laboratory study of hypoglycemia with 'human' and porcine insulin in diabetic patients reporting hypoglycemia unawareness after transferring to 'human' insulin. BMJ 1993;306:167-171.
93. Roth C, Landolt HP, Achermann P, Teuscher A, Borbély AA: Human versus porcine insulin in patients with insulin-dependent diabetes mellitus: differences in sleep and the sleep EEG during near-normoglycemia. Sleep 1998;21:92-100.
94. Kern W, Born J, Kerner W, Fehm HL: Different effects of human and porcine insulin-hypoglycaemia induced abnormalities of brainstem sensory function. Clin Phys Biochem 1990;8:122-127.
95. Galloway JA, Root MA, Bergstrom R, Spradlin CT, Howey DC, Fineberg SE, Jackson RL: Clinical pharmacologic studies with human insulin (recombinant DNA). Diabetes Care 1982;5(suppl 2):13-22.
96. Markussen, J, Damguard U, Johansen NL, Jorgensen KM, Soressen E, Thiro L: Charakterisierung des aus Schweineinsulin präparierten Humaninsulin. Aktuel Endokrinol 1981;1:104-114.
97. Chawdhury SA, Dodson EJ, Doson GG, Reynolds DC, Tolley SP, Blundell TL, Cleasby A, Pitty JE, Tickle IJ, Wood SP: The crystal of three nonpancreatic human insulins. Diabetologia 1983;25:460-464.
98. Kern W, Kerner W, Pietrowski R, Fehm HL, Born J: Effects of insulin and hypoglycaemia on the auditory brain stem response in humans. J Neurophysiol 1994;72:678-683.
99. Lewontin R, Fuller C: Genes in the Food: an Exchange. New York Review of Books, June 21, 2001.
100. As Lilly's synthetic insulin gets FDA OK, Novo, Biogen join to clone their own. Biotechnology Newswatch, Nov 15, 1982.
101. Marples A: Ironman/diabetic. Eli Lilly advertisement. Diabetes Dialogue, May/June/July 1986.
102. Sylvester R: Doctors attack 'inferior' NHS human insulin. The Sunday Telegraph, Jan 22, 1995.
103. Owens DR, Zinman B, Bolli GB: Insulins today and beyond. Lancet 2001;358:739-746.
104. Eli Lilly: News release. PR Newswire, July 21, 1980.
105. Miller HI: To America's Health: a Proposal to Reform the Food and Drug Administration. Stanford, Hoover Institution Press, Stanford University, 2000, pp 41-42.
106. US Food and Drug Administration: NDA 18,780 and 18,781, Medical Officers' Review (MOR) of New Drug Application (NDA), July 20, 1982.
107. Physician's Desk Reference: Product information: Humulin. Oradell, Medical Economics, 1987, pp 1142-1144.
108. BNF (British National Formulary), No 25. British Medical Association and The Royal Pharmaceutical Society of Great Britain, London, March 1993, p 255.
109. BNF (British National Formulary), No 52. September 2006, online edition http://www.bnf.org/ bnf/bnf/current/4081.htm (13.3.2007).
110. Annual Adverse Drug Experience Reports, Surveillance and Data Processing Branch, Division of Pharmacovigilance and Epidemiology Office of Epidemiology and Biostatistics Center for Drug Evaluation and Research. US Food and Drug Administration, 1969-1996.
111. Berger W, Pasquel M: Schlussbericht über die klinische Erfahrung mit dem Humaninsulinpräparat 'Ultratard', Dec 1984. Data on file Novo.
112. Galloway JA, Chance RE: Improving insulin therapy: achievements and challenges. Horm Metab Res 1994;26:591-598.
113. Herxheimer A: Human insulins: an update. Drug Ther Bull 1989;27:21-24.
114. International Diabetes Federation: Position Statement: Animal, Human and Analogue Insulins, March 2005. http://www.idf.org/home/index.cfm?node _ 1385. 1.3.2007.
115. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ. 1. Abschlussbericht A05-02. Köln:IQWiG;2007.
116. Birch VL (Vice President Europe North): Novo Nordisk insulin discontinuation information: an open letter from Novo Nordisk to all nurses in the United Kingdom. J Diabetes Nurs, June 2005.
117. BMJ Editors' Choice. BMJ, Sep 14, 1991, vol 303.
118. Herxheimer A: Human insulins: an update. Drug Ther Bull 1989;27:21-24.
119. BNF (British National Formulary), No 30. British Medical Association and The Royal Pharmaceutical Society of Great Britain, London, September 1995.
120. Richter B, Neises G: 'Human' insulin versus animal insulin in people with diabetes mellitus. Cochrane Library, 2002. http://www.cochrane.org.
121. Alberti G: Addressing the insulin challenges. Diabetes Voice 2002;47:4.
122. Siebenhofer A, Plank J, Berghold A, et al: Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Library, 2004. http://www.cochrane.org.
123. Eckardt K, May C, Koenen M, Eckel J: Enhanced mitogenic potency of insulin analogs in human fibroblasts and smooth muscle cells is mediated by IGF-l receptor signaling. Diabetes 2006;55(suppl 1):463.
124. International Diabetes Federation website: http://www.idf.org/home/index.cfm?node = 5 1.2.2007.
125. Sachs J, Kremer M: A cure for indifference. London Financial Times, May 5, 1999.
126. International Diabetes Federation: Position Statement: Animal, Human and Analogue Insulins, March 2005. http://www.idf.org/home/index.cfm?node = 1385. 1.3.2007.